Coherus Oncology
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Coherus Oncology sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
Coherus Oncology: 15 sponsored US clinical trials, 4 recruiting.
Coherus Oncology sponsors 15 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 9 completed. 4 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumor, with 2 trials.
Top-decile sponsor footprint
Coherus Oncology ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
9 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
15 total, page 1 of 1
A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
NCT06657144
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
NCT06679985
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
NCT06457503
Study of CHS-114 in Participants With Advanced Solid Tumors
NCT05635643
Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
NCT05757492
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
NCT05359861
Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer
NCT05177770
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
NCT04374877
Study of SRF617 in Patients With Advanced Solid Tumors
NCT04336098
Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta
NCT02650973
Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis
NCT02489227
Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®
NCT02418104
Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim)
NCT02385851
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
NCT02134210
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)
NCT02115750
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 3 |
| Phase 3 | 3 |
| Phase 4 | 1 |
What is open in the Coherus Oncology pipeline
4 recruiting of 15 indexed (27% open); 9 completed (60%).
Phase mix: 4 late (III/IV) vs 11 early (I/II) (early-phase heavy).
Top condition: Advanced Solid Tumor (2 trials), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Coherus Oncology: open-pipeline peers nationwide
Peers matched on 15 registered trials and 27% open enrollment, not the therapeutic-area sidebar.
Coherus Oncology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 trials (± recruiting share)
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors near 27% open enrollment (± trial volume)
- NewAmsterdam Pharma · 27% recruiting · 15 trials
- Portland VA Medical Center · 27% recruiting · 15 trials
- White River Junction Veterans Affairs Medical Center · 27% recruiting · 15 trials
- University of Illinois at Chicago · 27% recruiting · 430 trials
Related
What to do with this Coherus Oncology page
15 registered trials is a research-attention snapshot, not an endorsement of Coherus Oncology or any single study.
- 4 of Coherus Oncology's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Solid Tumor is the condition Coherus Oncology studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumor trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Coherus Oncology pipeline card: 15 registered trials from official public datasets.Report a data error.